Ceribell CTO Raymond Woo sells $47,535 in company stock

Raymond Woo, the Chief Technology Officer at Ceribell, Inc., transferred ownership of 1,979 shares of the company's common stock on August 21, 2026. Each share was sold for $24.02, resulting in a total sale value of $47,535. This transaction occurred as the stock price hovered near its 52-week high of $25.33, following a notable 109% growth over the previous year.

Analyzing the stock, InvestingPro concluded that it was overvalued at its current price based on Fair Value assessments. The shares were sold by Mr. Woo to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). After this sale, Mr. Woo now holds 194,729 shares of Ceribell common stock, including 1,026 shares obtained through the company's Employee Stock Purchase Plan on July 31, 2026.

For a more detailed analysis of Ceribell's valuation and performance, investors can refer to the comprehensive Pro Research Report available for this and over 1,400 other US equities on InvestingPro. In other recent news, Ceribell reported a Q2 revenue of $28.1 million for fiscal year 2026, representing a 33% increase year-over-year.

This growth was fueled by the expansion of its seizure-detection business and the introduction of new products targeting delirium monitoring and pediatric care. Despite the revenue boost, Ceribell reported a loss of $0.51 per share, exceeding the analyst's estimated $0.36 loss. In response to these results, Canaccord increased its price target for Ceribell shares from $25 to $26, while maintaining a Buy rating.

BTIG also adjusted its price target to $30 from $28, highlighting Ceribell's leadership in point-of-care rapid EEG and its recent FDA approval for pediatric and neonatal indications. The company added 32 accounts during the second quarter, slightly below Canaccord's estimate of 36 but driven by strong same-store utilization. The article was AI-generated and reviewed by an editor for accuracy.